| CAS NO: | 6493-06-7 |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Physical Appearance | A crystalline solid |
| Storage | Store at -20°C |
| M.Wt | 280.3 |
| Cas No. | 6493-06-7 |
| Formula | C13H20N4O3 |
| Synonyms | BL 194,CT-1501R,LSF |
| Solubility | ≤2mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide |
| Chemical Name | 3,7-dihydro-1-(5-hydroxyhexyl)-3,7-dimethyl-1H-purine-2,6-dione |
| Canonical SMILES | CC(O)CCCCn1c(=O)c2n(C)cnc2n(C)c1=O |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
(±)-Lisofylline is an anti-inflammatory agent.
Anti-inflammatory refers to the property of a agent or treatment reducing inflammation or swelling. Anti-inflammatory drugs make up about half of analgesics, remedying pain by reducing inflammation as opposed to opioids.
In vitro: (±)-Lisofylline is a potent anti-inflammatory agent in which only the (-) optical isomer is biologically active. (±)-Lisofylline was found to inhibit the generation of phosphatidic acid from cytokine-activated lysophosphatidic acyl transferase. (±)-Lisofylline could also suppress the production of the proinflammatory cytokine IFN-γ, inhibit IL-12-mediated STAT-4 activation, as well as enhance glucose-stimulated β-cell insulin secretion [1].
In vivo: In a previous study, lisofylline was administered to female non-obese diabetic mice for 3 weeks. Cytokines and blood glucose concentrations were monitored. Histology and immunohistochemistry were also carried out in pancreatic sections. Results showed that lisofylline was able to suppress IFN-γ production, reduce the onset of insulitis and diabetes, and inhibit diabetes [1].
Clinical trial: A clinical trial has been conducted to determine whether the administration of lisofylline would decrease mortality in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). However, this trial was stopped for futility at the first scheduled interim analysis. It was found that there was no significant difference between groups in the number of patients who had died at 28 days and there was no significant difference between the lisofylline and placebo groups in terms of ventilator-free days, infection-related deaths, resolution of organ failures, or development of serious infection [2].
References:
[1] Yang, Z. D.,Chen, M.,Wu, R., et al. The anti-inflammatory compound lisofylline prevents type I diabetes in non-obese diabetic mice. Diabetologia 45, 1307-1314 (2002).
[2] No authors listed. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2002 Jan;30(1):1-6.
m.cnreagent.com